PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:20 AM ET

Sponsor Check › Issuer

GS

GB SCIENCES INC

Corporation · organized in Nevada · formed more than five years before filing · Las Vegas, NV · formerly Growblox Sciences, Inc.; Signature Exploration & Production Corp.; Diabetic Treatment Centers of America, Inc.

$7.2Mreported sold (max)
60investors (max)
11offerings
11Form D filings
2014–2023filing years
0new, last 12 mo

Data last updated Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer Aug 2, 2023 · Courts (RECAP) last checked: Oct 24, 2026, 2:12 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

GB SCIENCES INC is a corporation organized in Nevada (formed more than five years before filing), based in Las Vegas, NV.

What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.

It has filed 11 Form D filings (11 originals, 0 amendments) for 11 offerings between Apr 2014 and Aug 2023. The latest filing of each offering reports a combined $24.9M sold of $33.5M offered to 191 investors; industry as reported: biotechnology; latest exemption Rule 506(b).

What this means A repeat filer — 11 separate raises over about 9 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).

Key people as listed: Andrea Small-Howard (executive officer and director), Edmond DeFrank (director), John Poss (executive officer and director), Zach Swarts (executive officer), Leslie Bocskor (director) and 5 more.

What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.

Reported money out: $2.88M in sales commissions and $4M of proceeds to officers, directors or promoters (latest filing per offering). Paid to sell it: Network 1 Financial Securities, Inc., Network 1 Financial Services, Inc., Network 1 Financial Services. Inc..

What this means $4M of investor money was reported as going to the people running the deal — about 16.1% of what was sold. The form does not say what for (fees, salaries, buying something from them); ask. $2.88M went to brokers for selling it (about 11.6% of what was sold).

Activity: 0 new offerings in the last 12 months; no amendment on file; latest filing Aug 2, 2023.

What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched GB SCIENCES INC.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA), property records (NYC, FL, IL and TX counties) — 1 court case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 11 public filings for GB SCIENCES INC and found 6 differences, 1 worth asking the sponsor about: 6 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for GB SCIENCES INC has not run yet — it is joining a line of 13,393 names; searches run around the clock at the hosts' allowed rate. Searched so far: 28 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

1 case: 1 dismissed

GrowBlox Sciences, Inc. v. GCM Administrative Services, LLC dismissed
District Court, S.D. New York · No. 1:14-cv-02280 · Filed Apr 1, 2014 · Closed Aug 24, 2016 · Nature of suit: 190 Contract: Other · Cause: 28:2201dj Declaratory Judgment
Role of GrowBlox Sciences, Inc.: Plaintiff · Outcome: Terminated 2016-08-24 — FJC Integrated Database disposition: Voluntarily dismissed Docket on CourtListener ↗
exact former company name; court in NY (not the issuer's state)
What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:12 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched GB SCIENCES INC..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:12 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

6 differences found between the filings for GB SCIENCES INC — 1 worth asking about (compared 11 filings on Oct 24, 2026)

Worth asking · Mar 24, 2017 – Aug 2, 2023

6 Form Ds were filed more than 15 days after the first sale

Form D filed 307 days after the first sale — GB SCIENCES INC · Form D filed 643 days after the first sale — GB SCIENCES INC · Form D filed 930 days after the first sale — GB SCIENCES INC · Form D filed 71 days after the first sale — GB SCIENCES INC · Form D filed 137 days after the first sale — GB SCIENCES INC · and 1 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Sources
Note · Jan 13, 2016 – Nov 28, 2017

John Poss's role changed at GB SCIENCES INC: executive officer → executive officer, director

The Jan 13, 2016 filing lists John Poss as executive officer; the Nov 28, 2017 Form D lists executive officer, director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Sources
Note · Mar 21, 2014 – Aug 2, 2023

6 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — GB SCIENCES INC (latest filing Aug 2, 2023) · No amendment in the last 12 months on an offering that may still be open — GB SCIENCES INC (latest filing Jun 3, 2022) · No amendment in the last 12 months on an offering that may still be open — GB SCIENCES INC (latest filing Oct 10, 2019) · No amendment in the last 12 months on an offering that may still be open — GB SCIENCES INC (latest filing Nov 28, 2017) · No amendment in the last 12 months on an offering that may still be open — GB SCIENCES INC (latest filing Jan 13, 2016) · and 1 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Sources
Note · Apr 1, 2014 – Jun 5, 2014

Address moved from Orlando, FL to Las Vegas, NV — GB SCIENCES INC

The people listed on the Apr 1, 2014 filing give Orlando, FL; on the Jun 5, 2014 filing they give Las Vegas, NV.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Sources
Note · Apr 1, 2014 – Oct 24, 2018

Reported revenue range changed between filings — GB SCIENCES INC

"No Revenues" (Apr 1, 2014); then "$1 - $1,000,000" (Nov 28, 2017); then "$1,000,001 - $5,000,000" (Oct 24, 2018).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Sources
Note · Apr 1, 2014 – Aug 2, 2023

Issuer used a different name before — GB SCIENCES INC

SEC records list prior names for this filer: Growblox Sciences, Inc.; Signature Exploration & Production Corp.; Diabetic Treatment Centers of America, Inc.. The current name on file is "GB SCIENCES INC".

What this means A name change is normal, but your documents may show the old name. Match the CIK, not just the name.

Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

10 of 11 offerings report sales commissions totalling $2,878,047; 0 report finder's fees; 10 report proceeds to related persons totalling $3,995,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Aug 2, 2023 D
File 021-488608
$100,000$0$60,000 (est.)Network 1 Financial Services, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Jun 3, 2022 D
File 021-448073
$56,500$0$75,000 (est.)Network 1 Financial Services, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Oct 24, 2019 D
File 021-351752
$0$0$0None listed on this filingEDGAR ↗
Oct 10, 2019 D
File 021-350807
$200,000$0$320,000 (est.)Network 1 Financial Services. Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Oct 10, 2019 D
File 021-350808
$720,000$0$1,150,000 (est.)Network 1 Financial Services. Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Oct 10, 2019 D
File 021-350809
$293,197$0$480,000 (est.)Network 1 Financial Services. Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Oct 24, 2018 D
File 021-324194
$500,000$0$800,000 (est.)Network 1 Financial Services, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Nov 28, 2017 D
File 021-299599
$506,350$0$800,000Network 1 Financial Services, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Jan 13, 2016 D
File 021-255114
$2,000$0$60,000 (est.)Network 1 Financial Services, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Jun 5, 2014 D
File 021-218604
$200,000$0$150,000 (est.)Network 1 Financial Services, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
Apr 1, 2014 D
File 021-214690
$300,000$0$100,000 (est.)Network 1 Financial Securities, Inc. BrokerCheck CRD 13577 ↗EDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Property records 0 documents · 0 ownership records · last checked Oct 23, 2026, 8:59 PM ET · NYC and Cook County lookup still to run

0 recorded documents and 0 ownership records matched to GB SCIENCES INC in the sources searched.

Not found in sources searched as of Oct 23, 2026, 8:59 PM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Florida DOR NAL roll (Hillsborough 39) roll year 2026 — loaded Oct 23, 2026, 8:54 PM ET; Florida DOR NAL roll (Dade 23) roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET; Harris County Appraisal District real_acct.txt roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET. Still to be looked up for this issuer: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.

Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Hillsborough County FL (recorded documents from Oct 14, 2026 forward; ownership from FL DOR roll 2026); Cook County IL (assessor ownership and deed/sale records, looked up per issuer when its page is viewed); Harris County TX and Dallas County TX (assessor ownership rolls only, 2026 roll; no deed, mortgage or sale records); Miami-Dade County FL (ownership from FL DOR roll only; Clerk recorded documents not covered). Recorder indexes for TX, AZ, IL and WA counties, mortgages and liens outside NYC and FL, lis pendens and foreclosure notices everywhere, Miami-Dade County FL recorded documents, Maricopa County AZ, King County WA, Salt Lake County UT, and all other counties are not covered — not searched. Last refresh by source: Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 23, 2026, 8:58 PM ET; Harris County Appraisal District real_acct.txt Oct 23, 2026, 8:58 PM ET; Florida DOR NAL roll (Dade 23) Oct 23, 2026, 8:58 PM ET; Florida DOR NAL roll (Hillsborough 39) Oct 23, 2026, 8:54 PM ET. NYC and Cook County are looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 3:30 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.

Offerings (SEC Form D)

Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.

Offerings at a glance — 11 offerings, 11 filings (one row per SEC file number)
File no.Original Form DLatest filingAmendmentsOffered (latest)Sold (latest)Industry (latest)
021-488608Aug 2, 2023 EDGAR ↗Aug 2, 2023 D EDGAR ↗0$1,000,000$75,000Biotechnology
021-448073Jun 3, 2022 EDGAR ↗Jun 3, 2022 D EDGAR ↗0$565,000$25,000Biotechnology
021-351752Oct 24, 2019 EDGAR ↗Oct 24, 2019 D EDGAR ↗0$240,000$240,000Biotechnology
021-350809Oct 10, 2019 EDGAR ↗Oct 10, 2019 D EDGAR ↗0$3,000,000$2,931,970Biotechnology
021-350808Oct 10, 2019 EDGAR ↗Oct 10, 2019 D EDGAR ↗0$7,200,000$7,200,000Biotechnology
021-350807Oct 10, 2019 EDGAR ↗Oct 10, 2019 D EDGAR ↗0$2,000,000$2,000,000Biotechnology
021-324194Oct 24, 2018 EDGAR ↗Oct 24, 2018 D EDGAR ↗0$5,000,000$5,000,000Biotechnology
021-299599Nov 28, 2017 EDGAR ↗Nov 28, 2017 D EDGAR ↗0$6,500,000$3,895,000Biotechnology
021-255114Jan 13, 2016 EDGAR ↗Jan 13, 2016 D EDGAR ↗0$3,000,000$20,000Biotechnology
021-218604Jun 5, 2014 EDGAR ↗Jun 5, 2014 D EDGAR ↗0$2,000,000$2,000,000Biotechnology
021-214690Apr 1, 2014 EDGAR ↗Apr 1, 2014 D EDGAR ↗0$3,000,000$1,500,000Biotechnology

Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.

Aug 2, 2023 D Biotechnology — $75,000 sold of $1,000,000 · 2 investors EDGAR ↗
FilingForm D filed Aug 2, 2023
SEC file no. 021-488608 · accession 0000939798-23-000001
Raise progress$75,000 sold of $1,000,000 offered (8%) · $925,000 remaining · first sale Jun 30, 2023
Filing timingDate of first sale: Jun 30, 2023 · Form D filed: Aug 2, 2023 (33 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale1,212 days (3.3 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors2 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredDebt; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $100,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $60,000 (est.)
Signed byJohn Poss, CEO (Aug 2, 2023)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $1,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 3, 2022 D Biotechnology — $25,000 sold of $565,000 · 1 investors EDGAR ↗
FilingForm D filed Jun 3, 2022
SEC file no. 021-448073 · accession 0000939798-22-000007
Raise progress$25,000 sold of $565,000 offered (4%) · $540,000 remaining · first sale May 20, 2022
Filing timingDate of first sale: May 20, 2022 · Form D filed: Jun 3, 2022 (14 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale1,618 days (4.4 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $56,500 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $75,000 (est.)
Signed byZach Swarts, CFO (Jun 3, 2022)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $565,000. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 24, 2019 D Biotechnology — $240,000 sold of $240,000 · 1 investors EDGAR ↗
FilingForm D filed Oct 24, 2019
SEC file no. 021-351752 · accession 0001445866-19-001262
Raise progress$240,000 sold of $240,000 offered (100%) · $0 remaining · first sale Oct 15, 2019
Filing timingDate of first sale: Oct 15, 2019 · Form D filed: Oct 24, 2019 (9 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale2,566 days (7.0 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$240,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byZach Swarts, CFO (Oct 23, 2019)
Market contextMinimum investment: $240,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $240,000. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 10, 2019 D Biotechnology — $2,931,970 sold of $3,000,000 · 17 investors EDGAR ↗
FilingForm D filed Oct 10, 2019
SEC file no. 021-350809 · accession 0001445866-19-001228
Raise progress$2,931,970 sold of $3,000,000 offered (98%) · $68,030 remaining · first sale Dec 7, 2018
Issuer's note: Offering is closed despite not having been fully sold out.
Filing timingDate of first sale: Dec 7, 2018 · Form D filed: Oct 10, 2019 (307 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale2,878 days (7.9 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors17 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services. Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $293,197 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $480,000 (est.)
Signed byZach Swarts, CFO (Oct 10, 2019)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $3,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 17. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 10, 2019 D Biotechnology — $7,200,000 sold of $7,200,000 · 60 investors EDGAR ↗
FilingForm D filed Oct 10, 2019
SEC file no. 021-350808 · accession 0001445866-19-001227
Raise progress$7,200,000 sold of $7,200,000 offered (100%) · $0 remaining · first sale Jan 5, 2018
Filing timingDate of first sale: Jan 5, 2018 · Form D filed: Oct 10, 2019 (643 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale3,214 days (8.8 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors60 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services. Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $720,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $1,150,000 (est.)
Signed byZach Swarts, CFO (Oct 10, 2019)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $7,200,000. Typical range: $2,000,000–$19,999,994.
Investors: 60. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 10, 2019 D Biotechnology — $2,000,000 sold of $2,000,000 · 21 investors EDGAR ↗
FilingForm D filed Oct 10, 2019
SEC file no. 021-350807 · accession 0001445866-19-001226
Raise progress$2,000,000 sold of $2,000,000 offered (100%) · $0 remaining · first sale Mar 24, 2017
Filing timingDate of first sale: Mar 24, 2017 · Form D filed: Oct 10, 2019 (930 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale3,501 days (9.6 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors21 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredDebt; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services. Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $200,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $320,000 (est.)
Signed byZach Swarts, CFO (Oct 10, 2019)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $2,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 21. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 24, 2018 D Biotechnology — $5,000,000 sold of $5,000,000 · 28 investors EDGAR ↗
FilingForm D filed Oct 24, 2018
SEC file no. 021-324194 · accession 0000939798-18-000027
Raise progress$5,000,000 sold of $5,000,000 offered (100%) · $0 remaining · first sale Aug 14, 2018
Filing timingDate of first sale: Aug 14, 2018 · Form D filed: Oct 24, 2018 (71 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale2,993 days (8.2 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors28 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $500,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $800,000 (est.)
Signed byKsenia Griswold, CFO (Oct 24, 2018)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 28. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Nov 28, 2017 D Biotechnology — $3,895,000 sold of $6,500,000 · 48 investors EDGAR ↗
FilingForm D filed Nov 28, 2017
SEC file no. 021-299599 · accession 0000939798-17-000093
Raise progress$3,895,000 sold of $6,500,000 offered (60%) · $2,605,000 remaining · first sale Jul 14, 2017
Filing timingDate of first sale: Jul 14, 2017 · Form D filed: Nov 28, 2017 (137 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale3,389 days (9.3 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors48 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredDebt; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $506,350 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $800,000
Signed byKsenia Griswold, Chief Financial Officer (Nov 28, 2017)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $6,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 48. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jan 13, 2016 D Biotechnology — $20,000 sold of $3,000,000 · 2 investors EDGAR ↗
FilingForm D filed Jan 13, 2016
SEC file no. 021-255114 · accession 0000939798-16-000100
Raise progress$20,000 sold of $3,000,000 offered (1%) · $2,980,000 remaining · first sale Dec 29, 2015
Filing timingDate of first sale: Dec 29, 2015 · Form D filed: Jan 13, 2016 (15 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale3,952 days (10.8 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors2 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: All States
Money to insidersSales commissions: $2,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $60,000 (est.)
Signed byJohn Poss, Chief Financial Officer (Jan 13, 2016)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $3,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 5, 2014 D Biotechnology — $2,000,000 sold of $2,000,000 · 1 investors EDGAR ↗
FilingForm D filed Jun 5, 2014
SEC file no. 021-218604 · accession 0000939798-14-000045
Raise progress$2,000,000 sold of $2,000,000 offered (100%) · $0 remaining · first sale Jun 2, 2014
Filing timingDate of first sale: Jun 2, 2014 · Form D filed: Jun 5, 2014 (3 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale4,527 days (12.4 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$1,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Services, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: CO
Money to insidersSales commissions: $200,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $150,000 (est.)
Signed bySteven Weldon, Chief Financial Officer (Jun 5, 2014)
Market contextMinimum investment: $1,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $2,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Apr 1, 2014 D Biotechnology — $1,500,000 sold of $3,000,000 · 10 investors EDGAR ↗
FilingForm D filed Apr 1, 2014
SEC file no. 021-214690 · accession 0000939798-14-000023
Raise progress$1,500,000 sold of $3,000,000 offered (50%) · $1,500,000 remaining · first sale Mar 21, 2014
Filing timingDate of first sale: Mar 21, 2014 · Form D filed: Apr 1, 2014 (11 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale4,600 days (12.6 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors10 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$1,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in NEVADA · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNetwork 1 Financial Securities, Inc. — FINRA BrokerCheck CRD 13577 ↗
Solicits in: CA, MN, NC, NJ, NV, OH, VA
Money to insidersSales commissions: $300,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.)
Signed bySteven Weldon, Chief Financial Officer (Apr 1, 2014)
Market contextMinimum investment: $1,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $3,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 10. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Aug 2, 2023. Industry as reported, by offering: All 11 offerings reported: Biotechnology (2014–2023).

Key people 10

Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.

NameRelationshipAddress stateOn filings (first → last)Also listed on
AH Andrea Small-HowardExecutive Officer, DirectorNVJan 13, 2016 → Aug 2, 2023
on 9 of 11 filings
listed on the latest filing
—
ED Edmond DeFrankDirectorNVJun 3, 2022 → Aug 2, 2023
on 2 of 11 filings
listed on the latest filing
—
JP John PossExecutive Officer, DirectorNVJan 13, 2016 → Aug 2, 2023
on 9 of 11 filings
listed on the latest filing
—
ZS Zach SwartsExecutive OfficerNVOct 10, 2019 → Jun 3, 2022
on 5 of 11 filings
not listed on the latest filing (Aug 2, 2023)
—
LB Leslie BocskorDirectorNVNov 28, 2017 → Oct 24, 2019
on 6 of 11 filings
not listed on the latest filing (Aug 2, 2023)
2 other issuers
ST Shane TerryDirectorNVNov 28, 2017 → Oct 24, 2019
on 6 of 11 filings
not listed on the latest filing (Aug 2, 2023)
—
KK Krin Ellery KuetheExecutive OfficerNVNov 28, 2017 → Oct 24, 2018
on 2 of 11 filings
not listed on the latest filing (Aug 2, 2023)
—
KG Ksenia GriswoldExecutive OfficerNVNov 28, 2017 → Oct 24, 2018
on 2 of 11 filings
not listed on the latest filing (Aug 2, 2023)
—
CE Craig EllinsExecutive Officer, DirectorNVApr 1, 2014 → Jan 13, 2016
on 3 of 11 filings
not listed on the latest filing (Aug 2, 2023)
2 other issuers
SW Steven WeldonExecutive Officer, DirectorNVApr 1, 2014 → Jun 5, 2014
on 2 of 11 filings
not listed on the latest filing (Aug 2, 2023)
1 other issuer

Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.

Connections

Other issuers listing the same people:

Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Adviser registration (Form ADV)

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched GB SCIENCES INC.

Meta advertising

No Meta Pixel ids or Facebook / Instagram page links on file for GB SCIENCES INC as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.

Public profiles

Public profiles official links and public statements, each with its source and date

No website or social profile named in GB SCIENCES INC's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #120,752 of 374,652 in line (14 issuers searched so far).

Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.

Entity standing: not checked (no official programmatic source for NV yet).

Export this report as PDF (all source links + data timestamp) · Premium

Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".

Corrections log

No corrections have been requested for this page.

Filing-to-filing changes are in Amendment history above.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Claim this profile · Facts policy

Email me the full report

The complete public-record profile for GB SCIENCES INC, plus the weekly new-filings list.

What do you want to do?

Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.

Request a correction

Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).

Sponsor response

Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.

Claim this profile (sponsors)

Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Las Vegas, NV). Each opens in a new tab; what you find there is not verified by PartnerFacts.